Cardiomyopathy secondary prevention: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cardiomyopathy}} | {{Cardiomyopathy}} | ||
{{AE}} [[User:Lina Ya'qoub|Lina Ya'qoub, MD]] | {{CMG}}; {{AE}} [[User:Lina Ya'qoub|Lina Ya'qoub, MD]]; {{EdzelCo}} | ||
ICD placement is also recommended for secondary prevention in patients who survived sustained ventricular tachycardia or ventricular fibrillation. | ICD placement is also recommended for secondary prevention in patients who survived sustained ventricular tachycardia or ventricular fibrillation. | ||
Latest revision as of 03:31, 27 October 2023
|
Cardiomyopathy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Guidelines |
|
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy |
|
Case Studies |
|
Cardiomyopathy secondary prevention On the Web |
|
American Roentgen Ray Society Images of Cardiomyopathy secondary prevention |
|
Risk calculators and risk factors for Cardiomyopathy secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Lina Ya'qoub, MD; Edzel Lorraine Co, DMD, MD[2]
ICD placement is also recommended for secondary prevention in patients who survived sustained ventricular tachycardia or ventricular fibrillation.
References
Template:WH Template:WS Template:CALISKAN, K. , SZILI‐TOROK, T. , THEUNS, D. A., KARDOS, A. , GELEIJNSE, M. L., BALK, A. H., VAN DOMBURG, R. T., JORDAENS, L. and SIMOONS, M. L. (2011), Indications and Outcome of Implantable Cardioverter‐Defibrillators for Primary and Secondary Prophy